Enanta Nominates EDP-239 as Lead Development Candidate for NS5A HCV Inhibitor Program

WATERTOWN, Mass., March 2 /PRNewswire/ -- Enanta Pharmaceuticals, Inc. announced today the nomination of lead development candidate, EDP-239, from its NS5A hepatitis C virus (HCV) inhibitor program. EDP-239 has demonstrated picomolar potency against multiple genotypes of the virus and a preclinical pharmacokinetic profile amenable to once-a-day...

Abbott and Enanta Announce Advancement of Hepatitis C Collaboration

WATERTOWN, Mass., March 2 /PRNewswire/ -- Enanta Pharmaceuticals, Inc. announced today the nomination of lead development candidate, EDP-239, from its NS5A hepatitis C virus (HCV) inhibitor program. EDP-239 has demonstrated picomolar potency against multiple genotypes of the virus and a preclinical pharmacokinetic profile amenable to once-a-day...

National Cancer Institute awards PDS Biotechnology $1.28M phase 2 SBIR contract

PDS Biotechnology Corporation today announced that the company has been awarded a $1.28M phase 2 SBIR contract by the National Cancer Institute division of the US National Institutes of Health. The contract provides funding to complete studies required to file an Investigational New Drug Application (IND) with the FDA for the company's lead human papillomavirus (HPV)-cancer product late in...

FDA warns of heart risk with HIV drug combination

(AP) -- The Food and Drug Administration issued a warning Tuesday about potential heart risks when combining two HIV...

Further doubt cast on virus link to chronic fatigue syndrome

Researchers investigating UK samples have found no association between the controversial xenotropic murine leukemia virus-related virus and chronic fatigue syndrome. Their study calls into question a potential link described late last year by an American research...

ReNeuron OK’d for world’s first stem cell trial for strokes

The UK's ReNeuron has been given a regulatory green light to launch the world's first human trial of a stem cell therapy for...

GeoVax Labs, Inc. Begins Enrollment at Final Site for Preventative Vaccine; Next Step Is to Submit IND Application for Therapeutic Vaccine to FDA

Hires Clinical Research Organization ATLANTA, Feb. 8 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today provided an update on its vaccine trials...

For Dekker, It’s Always Flu Season

When Cornelia Dekker, MD, was an intern in 1976, a surprise outbreak of swine flu at Fort Dix, N.J, set health care providers scrambling to immunize Americans against a possible epidemic. Instead of causing widespread disease, the virus disappeared as unexpectedly as it had come, piquing Dekker’s interest in the mysteries of influenza. After three decades of studying viral infections, Dekker, now professor of pediatrics in infectious disease at Stanford, again finds herself trying to...

Potential new class of drugs to combat hepatitis C identified

Scientists have discovered a novel class of compounds that, in experiments in vitro, inhibit replication of the virus responsible for hepatitis...

Unwanted guests: How herpes simplex virus gets rid of the cell’s security guards

A viral infection is like an uninvited, tenacious houseguest in the cell, using a range of tricks to prevent its eviction. Researchers at the Salk Institute for Biological Studies have identified one of the key proteins allowing herpes simplex virus (HSV) DNA to fly under the radar of their hosts' involuntary...